in-Pharmatechnologist spoke with James Botkin, EDT’s SVP of operations, who explained that the new offering, launched last month, is based on the manufacturing capacity and capabilities the firm has developed over the last forty years.
Botkin also said that the competitiveness of the new unit, which will focus on the production and development of oral solid dose drugs, is reliant on operating efficiencies established by its core drug delivery business.
He also suggested that, if successful, the OSD service will make EDT a more valuable proposition, which may make it more attractive to potential buyers if parent firm Elan restarts efforts to split the unit from its BioNeurology business.